Loading...

Table of Content

    30 September 2026, Volume 31 Issue 9
    Liver Fibrosis and Cirrhosis
    The clinical application value of combined measurement of liver and spleen stiffness in non-invasive assessment of fibrosis stages in chronic hepatitis B
    Wang Yiru, Ding Lei, Meng Fankun
    2026, 31(9):  1232-1235. 
    Asbtract ( 3 )   PDF (567KB) ( 0 )  
    References | Related Articles | Metrics
    Objective To explore the clinical application value of combined measurement of liver and spleen stiffness in the non-invasive assessment of liver fibrosis stages in chronic hepatitis B (CHB) patients. Methods A total of 123 CHB patients who underwent liver biopsy were enrolled in Beijing You'an Hospital, Capital Medical University. The spleen stiffness (SSM) and liver stiffness (LSM) of all patients were measured. With pathological results as the gold standard, the diagnostic value of combined liver and spleen stiffness for hepatitis B-related liver fibrosis staging was analyzed. Results Among 123 patients with hepatitis B, the number of patients at stages S0 to S4 was 18, 58, 16, 16, and 15 respectively. The LSM values were 4.30 (3.52, 6.00), 4.65 (3.80, 5.92), 7.50 (5.02, 7.97), 10.85 (9.07, 13.15), and 13.20 (11.50, 17.80) kPa, and the SSM values were 14.55 (13.42, 16.17), 14.30 (12.10, 18.22), 21.15 (16.82, 23.95), 22.85 (18.82, 27.05), and 30.50 (23.40, 40.00) kPa, respectively. Both LSM and SSM values increased with the progression of liver fibrosis, and the difference was statistically significant (P<0.001). LSM and SSM were both positively correlated with liver fibrosis stages (r=0.709 and 0.655, respectively; both P<0.001). The patients were divided into a significant fibrosis group (≥ stage S2) and a non-significant fibrosis group (≤stage S1). The optimal diagnostic cut-off values of LSM and SSM for diagnosing significant liver fibrosis (≥ stage S2) were 7.45 kPa and 20.65 kPa, respectively, with the areas under the receiver operating characteristic curve (AUC) being 0.919 and 0.909. The diagnostic efficacy of LSM for significant liver fibrosis (≥stage S2) was comparable to that of SSM, and the difference was not statistically significant (Z=0.314, P=0.075). The AUC of the combined use of LSM and SSM for diagnosing significant liver fibrosis (≥ stage S2) was 0.948. Compared with the single usage of LSM or SSM, the diagnostic efficacy was significantly improved, and the differences were statistically significant (Z=1.968 and 2.018, P=0.0491 and 0.0436, respectively). Conclusion The diagnostic efficacy of LSM and SSM measured by transient elastography for significant liver fibrosis (≥ stage S2) is comparable, and their combination can improve the diagnostic efficacy.
    The predictive value of lymphocyte-to-monocyte ratio in the prognosis of critically ill patients with liver cirrhosis based on the MIMIC database
    Shen Wenjuan, Yang Li, Luo Liang
    2026, 31(9):  1236-1242. 
    Asbtract ( 3 )   PDF (1393KB) ( 0 )  
    References | Related Articles | Metrics
    Objective To explore the impact and clinical significance of the lymphocyte-to-monocyte ratio (LMR) on 28-day mortality in cirrhotic patients in the ICU. Methods A retrospective analysis was conducted using data from 1,680 critically ill cirrhotic patients in the MIMIC-IV 2.0 database. Demographic information, clinical parameters, laboratory results, and clinical scores were collected. The LMR within 24 hours of ICU admission was calculated. All the patients were stratified into a low LMR group and a high LMR group based on the optimal cutoff value of LMR. The prognostic impact of LMR on 28-day mortality was assessed, and curve fitting analyses were performed to further explore the relationship between LMR and mortality. Results Among ICU patients with liver cirrhosis, the 28-day mortality rate was significantly higher in the low LMR group (LMR < 1.19) compared to that of the high LMR group (LMR ≥ 1.19) (39.2% vs. 23.1%). The incidence of sepsis and acute kidney injury (AKI) was also significantly higher in the low LMR group than that in the high LMR group (82.5% vs. 70.7% for sepsis; 77.2% vs. 65.4% for AKI). The survivors had higher LMR levels than non-survivors (2.68 vs. 2.12; P<0.001). By multivariate logistic regression analysis, after adjusting for potential confounders including sex, age, total bilirubin, albumin, creatinine, INR, and CCI score, it was showed that LMR ≥ 1.19 was associated with reduced 28-day mortality [OR (95% CI): 0.69 (0.52~0.92), P=0.01] when compared with LMR < 1.19. When grouped by tertiles, both the LMR 1.27~2.50 group and the LMR > 2.50 group were associated with decreased ICU mortality in cirrhotic patients [OR (95% CI) = 0.71 (0.56~0.89) and 0.70 (0.54~0.90)]. Conclusion The lymphocyte-to-monocyte ratio (LMR) is an independent predictor for 28-day mortality in critically ill patients with liver cirrhosis. Furthermore, a dose-response relationship was shown between LMR levels and the mortality risks, indicating a significant application value of LMR level in the risk stratification and decision-making intervention.
    An analysis on the etiologies and clinical characteristics of 3 185 hospitalized liver cirrhotic patients
    Zhao Fengcong, Yilihamu Abulitifu, Zhang Yongping
    2026, 31(9):  1243-1246. 
    Asbtract ( 3 )   PDF (416KB) ( 0 )  
    References | Related Articles | Metrics
    Objective To analyze the clinical features and etiologies of hospitalized liver cirrhotic patients. Methods This is a retrospective analysis on the clinical characteristics, etiologies, and complications of liver cirrhotic patients hospitalized in the Department of Infectious Diseases, People's Hospital of Xinjiang Uygur Autonomous Region from 2012 to 2021. Results A total of 3 185 hospitalized patients with cirrhosis were collected., age ranged from 14 to 96 years old, mean age was (54.6 ± 13.0) years old. Among the causes of liver cirrhosis, hepatitis B virus (HBV) infection was the leading factor accounting for 1,195 cases (37.5%) of the patients, followed by hepatitis C virus (HCV) infection [602 cases, 18.9%], and cryptogenic cirrhosis (CC) [460 cases, 14.4%]. A total of 2,040 cases (64.05%) of liver cirrhosis were associated with HBV and HCV infections. Within the CC patients, 29.7% had diabetes. The male patients had higher rates of cirrhosis caused by HBV, HCV, CC, alcoholic liver disease (ALD), and HBV combined with HCV than female patients (male/female percentage ratio: 75.6%/24.4%, 57.1%/42.9%, 56.5%/43.5%, 95.4%/4.6%, 77.3%/22.7%, respectively). Cirrhosis caused by autoimmune liver disease (AILD) and non-alcoholic fatty liver disease (NAFLD) was lower in male patients than those in female patients (male/female percentage ratio: 16.5%/83.5%, 39.2%/60.8%). All these differences are statistically significant (P<0.05). The main complications of liver cirrhotic patients were spontaneous peritonitis (418 cases, 13.1%), hepatic encephalopathy (326 cases, 10.2%), gastrointestinal bleeding (268 cases, 8.4%), primary liver cancer (243 cases, 7.7%), and hepatorenal syndrome (72 cases, 2.4%). Of the 243 cirrhotic patients with liver cancer, the top five etiologies were HBV infection (153 cases, 63.4%), HCV infection (44 cases, 18.1%), CC (23 cases, 9.5%), autoimmune liver diseases (AILD) (7 cases, 2.9%), and HBV infection combined with alcoholic liver disease (ALD) (6 cases, 2.5%). Conclusion In the present study, more men than women in patients with cirrhosis, and the mean age of male patients was younger than that of female patients. The top five causes of liver cirrhosis, in the order of prevalence, are HBV, HCV, CC, AILD, and ALD. The incidences of cirrhosis caused by AILD and NAFLD were lower in male patients than those in female patients. The complications of cirrhosis were spontaneous peritonitis, hepatic encephalopathy, gastrointestinal hemorrhage, liver cancer and hepatorenal syndrome successively. HBV infection is the leading etiology of liver cancer.
    The predictive value of Rockall score, Blatchford score, AIMS65 score and their combination on a short-term risk of upper gastrointestinal bleeding in cirrhotic patients
    Liu Pei, Zhang Shunling, Zeng Xueli, Li Xinyi, Zheng Sheng, Yang Juan
    2026, 31(9):  1247-1252. 
    Asbtract ( 3 )   PDF (719KB) ( 0 )  
    References | Related Articles | Metrics
    Objective To explore the predictive value of Rockall score, Blatchford score, AIMS65 score and their combined application on a short term risk of upper gastrointestinal bleeding (UGB) in liver cirrhotic patients. Methods One hundred and thirty-five patients with liver cirrhosis who were diagnosed and treated in the Second Affiliated Hospital of Dali University from January 2020 to July 2024 were selected, All patients were divided into a non-bleeding group (71 cases) and a bleeding group (64 cases) according to whether UGB occurred within 3 months' follow-up. The levels of Rockall score, Blatchford score, and AIMS65 score in these two groups were compared. Logistic regression analysis was used to identify the risk factors for the short term occurrence of UGB in the cirrhotic patients. ROC curve was used to analyze the predictive value of Rockall score, Blatchford score, AIMS65 score and the combined application of three scores on the risk of UGB in cirrhotic patients. Results The Rockall score [5.00 (3.25~6.00) vs. 1.00 (0~3.00)], Blatchford score [13.00 (9.25~15.00) vs. 7.00 (3.00~9.00)] and AIMS65 scoring level [2.00 (1.00~2.00) vs.1.00 (0~1.00)] in patients of the bleeding group were higher than those of the non-bleeding group (All P<0.001). Logistic regression analysis showed that liver function parameters, spleen thickness, portal vein internal diameter, Rockall score, Blatchford score, and AIMS65 score were independent risk factors affecting the occurrence of short-term UGB in cirrhotic patients (all P<0.05). Receiver Operating Characteristic (ROC) curve analysis showed that the area under curves (AUCs) of Rockall score, Blatchford score, and AIMS65 score alone for predicting the occurrence of short-term UGB in cirrhotic patients were 0.879 (95%CI: 0.822~0.936), 0.846 (95%CI: 0.784~0.908), and 0.867 (95%CI: 0.807~0.928), respectively, and the AUC of Rockall score, Blatchford score and AIMS65 score in combination for detecting the short-term occurrence of UGB in cirrhotic patients was 0.942 (95%CI: 0.903~0.980), which was superior to those predicted by each of them individually (P<0.05). Conclusion The combined application of Rockall score, Blatchford score, and AIMS65 score is valuable in assessing the short-term risk of UGB in patients with liver cirrhosis.
    A construction of a nomogram model to predict the risk of the first episode of occult hepatic encephalopathy in cirrhotic patients
    Gu Zhengtai, Liu Weiwei, Gu Lingyun, Ma Chenbin
    2026, 31(9):  1253-1257. 
    Asbtract ( 3 )   PDF (1124KB) ( 1 )  
    References | Related Articles | Metrics
    Objective To construct a nomogram model in order to predict the risk of the first episode of occult hepatic encephalopathy (CHE) in cirrhotic patients. Methods A total of 208 patients with cirrhosis who were admitted in Rugao Hospital between May 2021 and May 2023 were selected. The independent risk factors for first episode of CHE in cirrhotic patients were analyzed using multifactorial logistic regression. A predictive nomogram were further established based on these risk factors, and the internal data set was used for the calibration curve, decision curve and clinical impact curve analyses. Results Among the 208 patients, the prevalence rate of first-episode of covert hepatic encephalopathy (CHE) was 41.3%. Compared to non-CHE patients, CHE patients showed significantly higher proportions of diabetes (58.1% vs. 35.0%), ascites (37.0% vs.22.0%), and Child-Pugh grade B (39.5% vs. 22.1%), with statistically significant differences (P<0.05). The average age,handgrip strength, model for end-stage liver disease score, albumin-bilirubin score, and prothrombin time were (68.5±5.9) years, (21.89±3.36) kg, (9.57±5.38), (-2.07±0.48), (16.95±1.98) s for CHE patients, and (64.2±5.3) years, (23.29±3.99) kg, 7.12±4.36, -2.40±0.52, and (15.77±1.37) s for non-CHE patients, respectively. The blood urea nitrogen, platelet count, and albumin level were (7.11±1.93) mmol/L, (100.56±40.54) × 109/L, and (30.54±3.76) g/L in CHE patients, respectively, which were significantly higher than those of (6.40±2.48) mmol/L, (128.54±46.53) × 109/L, and (33.32±3.72) g/L in non-CHE patients (all P<0.05). Multivariate logistic regression analysis identified age, diabetes, handgrip strength, albumin, and blood urea nitrogen as independent risk factors for first-episode of CHE in cirrhotic patients (OR=1.628, 2.072, 3.326, 0.711, and 1.426, respectively; P<0.05). The calibration curve of the nomogram demonstrated excellent predictive accuracy with a C-index of 0.906. Decision curve analysis revealed that the nomogram provided clinically meaningful standardized net benefits within a risk threshold range of 0.153~0.876. The clinical impact curve analysis indicated that when the predicted probability threshold exceeded 40%, the nomogram's predictive accuracy closely approximated the actual observed outcomes. Conclusion In this study, a nomogram model constructed based on age, diabetes, handgrip strength, albumin, and blood urea nitrogen in cirrhotic patients was effective in quantifying the risk of a first episode of CHE in cirrhotic patients, which provided a method for healthcare professionals to assess the patient's condition and prognosis.
    Viral Hepatit
    The clinical characteristics of hemodialysis combined with antiviral therapy in hepatitis C patients
    Liu Haiyan, Zhao Naxin, Ren Wenwen, Liu Xiaoli, Zeng Zhili, Guo Hebing, Xiang pan
    2026, 31(9):  1258-1262. 
    Asbtract ( 3 )   PDF (461KB) ( 0 )  
    References | Related Articles | Metrics
    Objective To analyze the clinical characteristics of patients undergoing hemodialysis who received antiviral therapy for hepatitis C viral (HCV) infection. Methods Performed a retrospective analysis on the clinical data and treatment methods of five patients with HCV infection who underwent routine hemodialysis and received antiviral therapy between January 2022 and March 2023 at the blood purification center of Beijing Ditan Hospital affiliated to Capital Medical University. Results Among the 5 patients, two had chronic glomerulonephritis, one had ischemic nephropathy combined with diabetic nephropathy, one had neurogenic bladder, and one was highly possible to have diabetic nephropathy. All patients had a history of blood transfusion. Some patients underwent HCV genotype testing. Among them, one case was genotype 1b, one case was not successfully typed, and no laboratory test reports were found for the rest of patients. Before antiviral treatment, the viral load (HCV RNA) was detected. All 5 patients had a viral load greater than 105 IU/mL. Among them, three patients received sofosbuvir-velpatasvir antiviral therapy, one patient received interferon and sofosbuvir-velpatasvir antiviral therapy sequentially, and one patient received elbasvir-grazoprevir antiviral therapy against HCV. Among the 5 patients, four had chronic hepatitis C, one had decompensated cirrhosis. All of them obtained an early response. After antiviral therapy, sustained virological response was achieved in all five patients, and no adverse reactions occurred after taking the direct-acting antiviral drugs. Conclusion Direct-acting antiviral therapy is safe and effective in patients with severe renal insufficiency undergoing hemodialysis, and has no adverse effects on renal function.
    The effectiveness and safety of tenofovir disoproxil fumarate combined with neonatal dual immunoprophylaxis in preventing mother-to-child HBV transmission
    Ge Chunyan, Cao Xia, Youlituziayi Adili, You Chunxia
    2026, 31(9):  1263-1266. 
    Asbtract ( 6 )   PDF (387KB) ( 0 )  
    References | Related Articles | Metrics
    Objective To investigate the effectiveness and safety of tenofovir disoproxil fumarate (TDF) combined with neonatal dual immunoprophylaxis in preventing mother-to-child transmission of hepatitis B virus (HBV) among HBsAg-positive pregnant women with high viral loads. Methods A total of 94 HBsAg-positive pregnant women and their infants who received antenatal care and delivered at Nantong Third People's Hospital were enrolled. According to whether antiviral therapy was administered during pregnancy, all participants were divided into a combined prophylaxis group (n=43) and a standard prophylaxis group (n=51). The pregnant women in the combined group received oral TDF during mid-to-late pregnancy, whereas those in the standard group did not receive antiviral therapy. All newborns in both groups received hepatitis B immunoglobulin (HBIG) within 12 hours after birth and completed the full hepatitis B vaccination schedule at 0, 1, and 6 months. The HBV infection status of infants at 7~12 months of age, neonatal immune response, dynamic changes in maternal virological and biochemical parameters, and maternal and infant safety outcomes were compared between the two groups. Results At the 7~12 month follow-up, the rates of HBsAg and HBV DNA positivity were both 0 in the combined prophylaxis group, whereas 5 infants (9.8%) in the standard prophylaxis group were positive for HBsAg and/or HBV DNA (P<0.05). The median anti-HBs titer in infants was higher in the combined prophylaxis group than that in the standard group [356 (210, 620) mIU/mL vs. 185 (95, 402) mIU/mL, P<0.05], and the proportion of high-level immune response (≥1 000 mIU/mL) was greater (39.5% vs. 19.6%, P<0.05). At delivery, maternal HBV DNA levels were lower in the combined prophylaxis group than in the standard group [(3.2±1.1) lg IU/mL vs. (6.9±0.7) lg IU/mL, P<0.05], with a greater reduction in viral load [(4.4±1.1) lg IU/mL vs. (0.6±0.2) lg IU/mL, P<0.05]. There were no statistically significant differences between the two groups in maternal hepatic or renal dysfunction, pregnancy complications, or adverse neonatal outcomes (P>0.05). Conclusion Among HBsAg-positive pregnant women with high viral loads, TDF combined with neonatal dual immunoprophylaxis significantly reduces the rate of HBV mother-to-child transmission and improves the quality of neonatal immune responses to hepatitis B vaccination, without increasing maternal or neonatal adverse events, indicating a favorable clinical applicability.
    Liver Failure
    Predictive value of peripheral blood CCL5 combined with CXCL14 for survival outcomes in patients with hepatitis B virus-related decompensated cirrhosis complicated by liver failure
    Zhao Yanyan, Li Fuxiang, Liu Lulu
    2026, 31(9):  1267-1272. 
    Asbtract ( 3 )   PDF (681KB) ( 0 )  
    References | Related Articles | Metrics
    Objective This study aimed to investigate the predictive value of peripheral blood C-C motif chemokine ligand 5 (CCL5) combined with C-X-C motif chemokine ligand 14 (CXCL14) for survival outcomes in patients with hepatitis B virus-related decompensated cirrhosis (HBV-DC) complicated by liver failure (LF). Methods This prospective study included 106 patients with HBV-DC and LF (LF group) admitted to the Department of Gastroenterology of Nanjing Pukou People's Hospital between January 2022 and December 2024. According to cirrhosis staging, they were divided into the stage-3 group (n=37), the stage-4 group (n=41), and the stage-5 group (n=28). An additional 106 patients with HBV-DC without LF, 1:1-matched for admission time, were selected as the non-LF group. An enzyme-linked immunosorbent assay (ELISA) was used to measure peripheral blood levels of CCL5 and CXCL14. Levels of CCL5 and CXCL14 were compared across different cirrhosis stages in the LF group. Based on 90-day survival outcomes, patients were divided into the survival and the death groups. Multivariate logistic regression analysis was performed to identify factors influencing prognosis. Receiver operating characteristic (ROC) curve analysis was conducted to assess the predictive value of CCL5 and CXCL14, alone and in combination, for 90-day survival outcomes. Results Peripheral blood levels of CCL5 and CXCL14 in the LF group [9.39 (6.48, 13.47) ng/mL and 6.28 (3.99, 9.98) ng/mL] were significantly higher than those in the non-LF group [4.62 (3.66, 5.51) ng/mL and 3.23 (2.41, 3.98) ng/mL] (all P<0.001). CCL5 and CXCL14 levels increased progressively with cirrhosis severity across stages 3, 4 and 5 (all P<0.001). The 90-day mortality rate among HBV-DC patients with LF was 38.68% (41/106). Compared with the survival group, the death group had higher proportions of stage-5 cirrhosis (48.78% vs. 12.31%), hepatic encephalopathy (26.83% vs. 9.23%), sepsis (24.39% vs. 4.62%), gastrointestinal variceal bleeding (70.73% vs. 41.54%) and higher MELD scores (28.85 ± 6.89 vs. 21.95 ± 4.93), as well as elevated levels of CCL5 [13.63 (9.85, 15.50) ng/mL vs. 7.31 (4.38, 9.98) ng/mL] and CXCL14 [10.03 (6.80, 12.03) ng/mL vs. 4.91 (2.31, 7.41) ng/mL] (all P<0.05). Multivariate analysis identified sepsis [OR (95%CI): 5.985 (1.951~18.354), P=0.002], gastrointestinal variceal bleeding [OR (95%CI): 4.346 (1.283~14.720), P=0.018], MELD score [OR (95%CI): 1.357 (1.108~1.663), P=0.003], CCL5 [OR (95%CI): 1.934 (1.353~2.764), P<0.001] and CXCL14 [OR (95%CI): 1.962 (1.367~2.814), P<0.001] as independent risk factors for death. The area under the ROC curve (AUC) for CCL5, CXCL14, and their combination in predicting survival was 0.844, 0.833, and 0.936, respectively; the combined model outperformed either marker alone (Z=2.909 and 3.024, P=0.004 and 0.003, respectively). Conclusion Elevated peripheral blood levels of CCL5 and CXCL14 are closely associated with worsening cirrhosis and poor survival outcomes in patients with HBV-DC complicated by LF. The combination of CCL5 and CXCL14 enhances the predictive value for survival outcomes.
    Risk factors and prognosis of HBV-related acute-on-chronic liver failure complicated with acute kidney injury
    Gong Jin, Zheng Weizhi, Chen Li, Zhang Kai
    2026, 31(9):  1273-1276. 
    Asbtract ( 4 )   PDF (405KB) ( 0 )  
    References | Related Articles | Metrics
    Objective This study aimed to collect the clinical data of hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF), find out the occurrence of acute kidney injury (AKI), and analyze its influencing factors and its influence on the clinical outcome. Methods 110 patients with HBV-ACLF diagnosed and treated in Nanjing Jiangning Hospital and Jiangsu Provincial People's Hospital from January 2021 to June 2025 were reviewed. Clinical data and clinical outcomes were compare between patients with and without HBV-ACLF complicated with AKI. Multivariate analysis was performed to indentify the independent risk factors of HBV-ACLF complicated with AKI, and the ability of the above risk factors to distinguish HBV-ACLF complicated with AKI was evaluated. Results The incidence of HBV-ACLF complicated with AKI was 25.4% (28/110). The age of patients with AKI was (53.1±7.2) years, which was significantly higher than that of patients without AKI [(47.8±5.4) years, P<0.05]. There were 6 cases (21.4%), 20 cases (71.4%) and 9 cases (32.1%) complicated with other organ failure, hepatic encephalopathy and spontaneous bacterial peritonitis (SBP) in the AKI group; They were significantly higher than those in the group without AKI [4 cases (4.9%), 28 cases (34.1%) and 6 cases (7.3%)], and the difference was statistically significant (P<0.05). The scores of TBil, BUN, sCr, CTP and MELD in the AKI group were (202.6±43.5) μmol/L, (13.2±3.3) mmol/L, (147.9±36.7) μmol/L, (11.6±1.7) points and (27.0±4.8) points, compared with the group without AKI [(134.6±34.7) μmol/L, (6.5±2.5) mmol/L, (71.2±20.3) μmol/L, (8.7±1.4) points and (20.1±3.0) points]. The difference was statistically significant (P<0.05). The above indicators with statistically significant differences (P<0.05) were brought into multivariate analysis, and the screened variables included age, other organ failure, hepatic encephalopathy, SBP, TBil, BUN, sCr, CTP score and MELD score. After multivariate analysis, it was found that the independent risk factors of HBV-ACLF complicated with AKI were sCr, CTP score and MELD score (P<0.05). After 90 days' follow-up, 16 patients with HBV-ACLF complicated with AKI died, with a mortality rate of 57.1%, while 18 patients without AKI died, with a mortality rate of 21.9%. The difference was statistically significant (P<0.05). The cutoff points of sCr, CTP score and MELD score to distinguish whether HBV-ACLF patients are complicated with AKI were 108.9 μmol/L, 9.4 points and 23.2 points respectively. The AUC value of AKI diagnosed by sCr was significantly higher than the CTP score and MELD score (P<0.05). The sensitivity, specificity and AUC of sCr in diagnosing HBV-ACLF complicated with AKI were 82.1%, 81.7% and 0.86, respectively. Conclusion More than 1/4 ACLF patients will be complicated with AKI. Abnormal sCr, CTP score and MELD score will significantly increase the risk of AKI in HBV-ACLF patients, which needs serious prevention and timely treatment to improve the success rate of clinical treatment.
    Development of a nomogram prediction model for multidrug-resistant infection in patients with HBV-related acute-on-chronic liver failure
    Chen Lingxin, Li Na, Ma Congxian, Tang Xiaohong, Liu Cuihua
    2026, 31(9):  1277-1282. 
    Asbtract ( 4 )   PDF (1611KB) ( 0 )  
    References | Related Articles | Metrics
    Objective This study aimed to develop and validate a nomogram for predicting multidrug-resistant organism (MDR) infection in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF), so as to provide an evidence-based tool for the targeted prevention of MDR infections. Methods A retrospective study was conducted on patients with HBV-ACLF (diagnosed according to the EASL and APASL 2019 criteria), admitted to Mianyang Hospital and Mianyang Central Hospital between January 2021 and January 2025. MDR infections occurring during hospitalization were assessed. Clinical data, including age, gender, BMI, smoking, and alcohol history, were collected from electronic medical records. Multivariable logistic regression was used to identify independent risk factors for MDR infection and to construct a nomogram. The model's performance was assessed using calibration curves, the receiver operating characteristic (ROC) curve, and decision curve analysis (DCA). Results The study included 295 HBV-ACLF patients; 182 (61.69%) were male and 113 (38.31%) were female. MDR infection occurred in 56 patients, with an incidence of 18.98%. Multivariable analysis identified the following independent risk factors (all P<0.05): high COSSH-ACLF score (OR=2.781, 95% CI: 1.539~5.027), use of broad-spectrum antibiotics for ≥7 days (OR=2.221, 95% CI: 1.256~3.929), exposure to carbapenems (OR=1.827, 95% CI: 1.104~3.024), glucocorticoid therapy (OR=1.505, 95% CI: 1.039~2.180), and multiple organ failure (OR=1.424, 95% CI: 1.033~1.965). The developed nomogram demonstrated good performance: the calibration curve showed high agreement between predicted and actual probabilities (mean absolute error = 0.009), the C-index was 0.885, and the area under the ROC curve was 0.885 (95% CI: 0.698~0.783) with a sensitivity of 0.857 and specificity of 0.899. Decision curve analysis indicated a superior net benefit within a risk threshold probability range of 0.05 to 0.40. Conclusion The constructed nomogram provides a reliable tool with good calibration, discrimination, and potential clinical utility for predicting the risk of MDR infection in patients with HBV-ACLF.
    Clinical application research of non-biological artificial liver therapy primarily utilizing the DPMAS mode in treating pre-and early liver failure
    Zhao Tingting, Zhang Fenna, Lv Beibei, Song Yujuan, He Na
    2026, 31(9):  1283-1292. 
    Asbtract ( 3 )   PDF (1008KB) ( 0 )  
    References | Related Articles | Metrics
    Objective This study aimed to explore the clinical application value of non-biological artificial liver therapy primarily utilizing the double plasma molecular adsorption system (DPMAS) in treating pre- and early-stage liver failure. Methods Clinical materials of 170 patients, who were diagnosed with liver failure at the department of hepatology at the First Affiliated Hospital of Xi'an Medical University and Xi'an International Medical Center, as well as the Department of Hepatology at Yulin Traditional Chinese Medicine Hospital, were retrospectively collected and divided into DPMAS group (120 cases received medical treatment combined DPMAS, including 50 in pre- and early-stage, 50 in middle stage, and 20 in the end stage) and control group (50 cases received medical treatment) according to their treatment. Then, the feasibility and clinical benefit degree of DPMAS were analyzed according to the indices of liver and kidney function, coagulation function, inflammatory levels, extrahepatic complications, and survival rates of patients between different groups and different stages. Results Compared with the control group, the DPMAS group could significantly ameliorate the indices of liver and kidney and coagulation function, including alanine aminotransferase [(70.32±29.40) vs. (146.94±46.53)](U/L), aspartate aminotransferase [(59.20±21.63) vs. (122.27±41.84)](U/L), total bilirubin [(98.37±36.95) vs. (135.03±41.04)](μmol/L), creatinine [(61.30±12.82) vs. (66.80±7.82)](μmol/L), international normalized ratio [(1.40±0.06) vs. (1.56±0.29)] and prothrombin activity [(70.3%±13.82%) vs. (60.21%±15.00%)](all P<0.05), reduce the inflammatory associated C-reactive protein [(11.72±1.94) vs. (15.69±2.10)](mg/L), tumor necrosis factor [(22.53±6.50) vs. (42.85±16.85)](mg/L), and interleukin-6 [(16.88±2.03) vs. (30.69±5.59)](ng/L) (all P<0.001), and hepatic encephalopathy incidence (0% vs. 2%, P=0.016), and improve the 12-week and 24-week survival rates (90% vs. 80%, 88% vs. 76%, P=0.048, 0.030) of patients with the pre-and early-stage liver failure. In the comparison of different stages, the improvement degrees of liver and kidney functions, coagulation and inflammatory indicators of patients in the pre- and early-stage after DPMAS treatment were significantly better than those in the middle and late stages (P<0.001), the incidence of extrahepatic complications was lower (P<0.001), and the 24-week survival rate was significantly higher than that in the middle stage and the late stage (88% vs. 60% vs. 20%, P<0.001). Conclusion Pre- and early-stage liver failure represents a priority time for the non-biological artificial liver mainly based on DPMAS in treating liver failure. It can effectively improve the liver and kidney functions, coagulation and inflammatory status of patients, reduce the risk of complications and increase the long-term survival rate.
    Liver Cancer
    Translational therapeutic effect of percutaneous radiofrequency ablation-assisted modified two-step hepatectomy with liver separation in the treatment of borderline resectable liver cancer
    Chen Yao, He Yan'an, Tang Bo, Zhu Yong
    2026, 31(9):  1293-1298. 
    Asbtract ( 3 )   PDF (695KB) ( 0 )  
    References | Related Articles | Metrics
    Objective This study aimed to explore the translational therapeutic effect of percutaneous radiofrequency ablation (PRFA) -assisted modified two-step hepatectomy with liver separation in the treatment of borderline resectable liver cancer. Methods A prospective cohort study was conducted on 86 patients with borderline resectable liver cancer admitted to Jiangyou People's Hospital, Sichuan Province from March 2022 to March 2024. They were randomly divided into 2 groups by the random number table method. The control group (n=43) underwent traditional associating liver partition and portal vein ligation for staged hepatectomy (ALPPS). The observation group (n=43) used PRFA-assisted liver separation in the first stage of ALPPS. The perioperative indicators of the patients were statistically analyzed. The changes in liver function and liver volume after surgery between the two groups were compared, and the postoperative complications of the patients were statistically analyzed. All patients were followed up for one year, and the recurrence and progression-free survival of the patients during this period were statistically analyzed. Results Compared with the control group, the operation time of the first stage [(217.26±35.37) vs. (141.22±23.54) h], intraoperative blood loss [(378.56±85.46) vs. (95.33±10.29) mL], incision length [(23.97±4.35) vs. (17.25±3.66) cm], intraoperative blood loss in the second stage [(638.71±85.43) vs. (545.26±80.95) mL], the interval between procedures [(18.26±3.71) vs. (15.21±4.95) d] and length of hospital stay [(15.95±2.06) vs. (13.35±2.33) d] were shortened (P<0.05). Compared with the control group, the levels of ALT and AST in the observation group increased [(659.43±61.26) vs. (890.56±55.79) U/L at 1 day after the first stage of operation (584.59±62.43) vs.(675.56±96.51) U/L](P<0.05). There was no statistically significant difference in FLR and F/S levels between the two groups at each time point (P<0.05). The total incidence of postoperative bile leakage and postoperative complications in the observation group was lower than that in the control group (13.95% vs.0; 41.86% vs. 16.28%) (P<0.05). The postoperative recurrence rate in the observation group (17.50%) was lower than that in the control group (21.05%) (χ2=0.158, P=0.691). Kaplan-Meier survival analysis showed that there was no statistically significant difference in the progression-free survival curves between the two groups (Log-Rank χ2=0.121, P=0.718). Conclusion PRFA-assisted ALPPS in the treatment of borderline resectable liver cancer patients can reduce intraoperative blood loss and incision length, shorten operation time, operation interval and hospital stay, increase postoperative liver volume, and reduce the occurrence of primary complications.
    Relationship between pre-operative contrast enhanced ultrasound parameters, NLR, PNI and postoperative recurrence in patients with AFP negative hepatocellular carcinoma
    Hu Zhiping, Fu Haoyun, Zeng Jianhong
    2026, 31(9):  1299-1303. 
    Asbtract ( 3 )   PDF (485KB) ( 0 )  
    References | Related Articles | Metrics
    Objective This study aimed to explore the correlations of preoperative contrast-enhanced ultrasound (CEUS) parameters, neutrophil-to-lymphocyte ratio (NLR) and prognostic nutritional index (PNI) with postoperative recurrence in patients with alpha-fetoprotein (AFP)-negative hepatocellular carcinoma (HCC). Methods A total of 69 AFP-negative HCC patients who underwent partial hepatectomy at Hubei Cancer Hospital from May 2018 to May 2021 and developed recurrence within 3 year postoperative follow-up were enrolled into the recurrence group. Meanwhile, 81 patients receiving partial hepatectomy without recurrence during the 3-year follow-up were assigned to the non-recurrence group. All subjects underwent preoperative CEUS examination and peripheral blood detection of NLR and PNI before the initial operation. Differences in the above-mentioned indicators were compared between the two groups. Multivariate logistic regression analysis was adopted to identify risk factors for postoperative HCC recurrence. Results The primary tumor diameter was markedly larger in the recurrence group than in the non-recurrence group [(4.51±0.93) cm vs. (3.83±0.86) cm, P<0.001]. Statistically significant inter-group differences existed in the distribution of LI RADS classification (χ2=5.051, P=0.025). The recurrence group had a higher proportion (65.22%, 45/69) of high-risk grade 5/6 lesions, whereas most patients (53.09%, 43/81) in the non-recurrence group fell within grade 3/4. The percentage of patients with NLR ≥2.52 reached 62.32% (43/69) in the recurrence group, which was higher than 44.44% (36/81) in the non-recurrence group (χ2=4.775, P=0.029). The rate of PNI<45.95 was 65.22% (45/69) for the recurrence group versus 38.27% (31/81) for the non-recurrence group, with significant statistical difference (χ2=10.823, P=0.001). Logistic regression demonstrated that enlarged primary tumor diameter, LI RADS grade 5-6, NLR ≥2.52, PNI<45.95 and TNM stage Ⅲ were independent risk factors for postoperative recurrence of HCC (P<0.05). Conclusion AFP negative HCC patients with postoperative recurrence present elevated preoperative NLR, reduced PNI, as well as distinct differences in tumor diameter and LI RADS grades on CEUS compared with non-recurrent cases. The above indicators are closely correlated with tumor recurrence after hepatectomy.
    The expression of HSPA5 and IGF2R in liver cancer tissue and their relationship with clinical pathological features and prognoses
    Shi Mingliang, Liu Zhekui, Feng Xiaoli
    2026, 31(9):  1304-1309. 
    Asbtract ( 4 )   PDF (2787KB) ( 0 )  
    References | Related Articles | Metrics
    Objective To explore the relationships between the expression of heat shock protein A5 (HSPA5), insulin-like growth factor 2 receptor (IGF2R) in liver cancer patients and their clinical pathological features and prognoses. Methods From April 2021 to April 2022, 145 liver cancer patients in the First Affiliated Hospital of Henan University were included. Their liver cancer tissues and paracancerous tissues were collected, and the clinicopathological characteristics such as microvascular invasion, TNM staging, Barcelona clinic liver cancer (BCLC) staging and the 3-year survival rate were recorded. The liver cancer patients were further divided into a survival group and a death group. The CPTAC database was used to retrieve the expression of HSPA5 and IGF2R in liver cancer tissues. Immunohistochemistry was performed to detect the HSPA5 and IGF2R expressions in tissues. Kaplan-Meier method was used to explore the relationship between the HSPA5 and IGF2R expression in liver cancer tissues and prognoses. Cox regression analysis was used to screen for the prognostic factors of patients with liver cancer. Results The research of the CPTAC database revealed that the expression of HSPA5 in liver cancer tissue was not significantly different from that in normal liver tissue (P>0.05), while the expression of IGF2R was significantly higher than that in normal liver tissue (P<0.05). The immunohistochemical staining results showed that the positive expression rates of HSPA5 and IGF2R in liver cancer tissue were higher than those in paracancerous tissues (P<0.05). Patients with positive expression of HSPA5 and IGF2R had higher proportions of microvascular invasion, TNM stage Ⅲ~Ⅳ, poor tissue differentiation, and BCLC stage C~D compared with those with negative expression (P<0.05). Liver cancer patients with positive expression of HSPA5 and IGF2R proteins (57.45%, 58.49%) had prominently lower 3-year survival rate than that of patients with negative expression (80.39%, 84.62%) (P<0.05). The death group had higher proportions of TNM stage Ⅲ~Ⅳ, poor tissue differentiation, and BCLC stage C~D than that in the survival group (P<0.05). Positive expression of HSPA5 (HR=2.978, 95%CI: 1.578~5.620), IGF2R (HR=3.054, 95%CI: 1.373~6.795) and TNM stage Ⅲ~Ⅳ (HR=3.015, 95%CI: 1.393~6.526) were independent influencing factors for 3-year mortality in patients with liver cancer (P<0.05). Conclusion HSPA5 and IGF2R are highly expressed in liver cancer tissue, and they are related to microvascular invasion, TNM staging, tissue differentiation degree, BCLC staging, and prognosis.
    Value of combined detection of AFP, AFP-L3%, and PIVKA-Ⅱ in therapeutic monitoring and prognostic assessment of hepatocellular carcinoma
    Wang Xiang, Ju Chenghui, Wang Gen
    2026, 31(9):  1310-1313. 
    Asbtract ( 4 )   PDF (459KB) ( 0 )  
    References | Related Articles | Metrics
    Objective To investigate the clinical value of combined detection of alpha-fetoprotein (AFP), lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3%), and protein induced by vitamin K absence or antagonist-Ⅱ (PIVKA-Ⅱ) in monitoring therapeutic response and evaluating prognosis in patients with hepatocellular carcinoma (HCC). Methods A total of 98 patients with HCC from Gaochun People's Hospital were enrolled. Serum levels of AFP, AFP-L3%, and PIVKA-Ⅱ were measured before and after treatment, and all patients underwent imaging follow-up. According to the modified Response Evaluation Criteria in Solid Tumors (mRECIST), patients were classified into complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) groups. Baseline levels and dynamic changes of tumor biomarkers were compared among different response groups. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive value of biomarker change rates for disease progression, and the associations between combined biomarker detection and progression-free survival (PFS) as well as 1-year overall survival (OS) were further analyzed. Results Significant differences in baseline levels of AFP, AFP-L3%, and PIVKA-Ⅱ were observed among patients with different mRECIST response categories (all P<0.05), and the levels showed a gradual increasing trend as therapeutic response worsened from CR and PR to SD and PD. After treatment, the decline rates of AFP in the CR and PR groups were 82.6% (71.4%, 92.3%) and 64.8% (48.2%, 78.9%), respectively, which were significantly higher than those in the SD group [23.4% (8.7%, 39.6%)] and the PD group [-12.6% (-38.4%, 5.9%)] (P<0.05). The decline rates of AFP-L3% were 71.3% (56.8%, 85.1%), 52.6% (36.4%, 69.8%), 18.9% (6.4%, 32.5%), and -6.7% (-21.3%, 8.4%) in the CR, PR, SD, and PD groups, respectively (P<0.05). The decline rates of PIVKA-Ⅱ were 79.4% (62.1%, 88.6%), 61.7% (45.8%, 75.3%), 21.6% (7.9%, 35.4%), and -15.8% (-41.7%, 3.6%) in the four groups, respectively (P<0.05). ROC curve analysis showed that the AUC values of AFP, AFP-L3%, and PIVKA-Ⅱ change rates for predicting disease progression were 0.74 (95% CI: 0.64~0.84), 0.77 (95% CI: 0.68~0.86), and 0.80 (95% CI: 0.71~0.89), respectively, while the combined detection of the three indicators yielded an AUC of 0.89 (95% CI: 0.82~0.96). Prognostic analysis revealed that patients with concurrent decreases in AFP, AFP-L3%, and PIVKA-Ⅱ had a median PFS of 18.4 (12.6, 25.8) months, which was significantly longer than that in patients with decreases in any two markers [11.2 (7.4, 16.3) months] and those with a decrease in ≤1 marker [6.3 (3.1, 9.8) months] (P<0.05). The corresponding 1-year OS rates were 85.0%, 63.8%, and 38.7%, respectively (P<0.05). Conclusion AFP, AFP-L3% and PIVKA-Ⅱ exhibit dynamic changes consistent with imaging-based therapeutic response during the treatment of hepatocellular carcinoma. Combined detection of these biomarkers provides substantial clinical value in therapeutic monitoring, prediction of disease progression, and prognostic assessment, and may serve as a useful complement to imaging evaluation.
    Application of multiparametric MRI in differentiating benign and malignant hepatic tumors
    Yang Fan, Cheng Yitao, Wang Lizhi, Lin Weixin
    2026, 31(9):  1314-1318. 
    Asbtract ( 4 )   PDF (516KB) ( 0 )  
    References | Related Articles | Metrics
    Objective To investigate the value of multiparametric magnetic resonance imaging (MRI) in differentiating benign and malignant hepatic tumors, and to evaluate the diagnostic performance of conventional MRI features, dynamic contrast-enhanced characteristics, and diffusion-weighted imaging (DWI)/intravoxel incoherent motion (IVIM) parameters. Methods A total of 201 patients from the Yingshang County People's Hospital and Wujin Hospital of Traditional Chinese Medicine with hepatic lesions confirmed by pathology or imaging follow-up were retrospectively included, comprising 44 cases of hepatic hemangioma (HH), 68 cases of focal nodular hyperplasia (FNH), 55 cases of hepatocellular carcinoma (HCC), and 34 cases of liver metastases. Conventional MRI, DWI and/or dynamic contrast-enhanced scanning were performed. Clinical characteristics and MRI features were compared among groups. Apparent diffusion coefficient (ADC) and perfusion fraction (f value) were measured. Logistic regression analysis was performed to identify independent predictors for differentiating benign and malignant tumors. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic performance of individual parameters and the combined model. Results Significant differences were observed among the groups in age, lesion diameter, AFP levels, liver function indices, and MRI features (all P<0.05). The HCC group was significantly older than the HH and FNH groups [(58.9±11.2) years vs. (45.2±10.6) years and (38.7±9.4) years], and AFP levels were markedly elevated [356 (78, 1 250) ng/mL vs. 3.8 (2.2, 6.1) ng/mL and 4.5 (2.8, 6.9) ng/mL, P<0.05]. Conventional MRI showed that benign lesions were more likely to present with well-defined margins and regular morphology, whereas malignant lesions were frequently associated with irregular borders and necrosis. On dynamic contrast-enhanced MRI, HH predominantly exhibited progressive enhancement (90.3%), FNH mainly showed persistent enhancement (88.1%), while HCC and metastatic tumors commonly demonstrated portal venous washout patterns (82.3% and 58.1%, respectively). DWI/IVIM analysis revealed that ADC and f values were significantly higher in benign lesions than in malignant lesions. The highest ADC value was observed in the HH group [(1.98±0.32) ×10-3 mm2/s], whereas the lowest was found in the metastatic tumor group [(0.98±0.18) ×10-3 mm2/s]. The highest f value was observed in the FNH group (35.8±7.2)%, while the lowest was observed in the metastatic tumor group (20.7±4.8)% (all P<0.05). Multivariate logistic regression analysis demonstrated that portal venous washout (OR=8.59, 95%CI: 3.41~21.62), rim enhancement (OR=6.62, 95%CI: 2.73~16.02), and ADC value (OR=0.09, 95%CI: 0.03~0.25) were independent predictors for differentiating benign and malignant hepatic tumors (all P<0.05). ROC analysis showed that the combined multiparametric MRI model achieved the highest diagnostic performance, with an AUC of 0.95, sensitivity of 90.2%, and specificity of 88.6%. Conclusion Multiparametric MRI can comprehensively reflect the biological characteristics of hepatic tumors from morphological, diffusion, and perfusion perspectives, and has high diagnostic value in differentiating benign and malignant lesions. The combined analysis of multiple parameters significantly improves diagnostic performance and provides an important basis for noninvasive clinical diagnosis.
    Development and clinical value of a model for predicting the risk of liver metastasis based on ultrasound blood flow imaging of primary colorectal cancer lesions combined with ultrasound quantitative scoring
    Fan Lili, Lan Qiyu, Liu Xuelian, Zeng Zhuohua
    2026, 31(9):  1319-1324. 
    Asbtract ( 3 )   PDF (985KB) ( 0 )  
    References | Related Articles | Metrics
    Objective By analyzing ultrasound blood flow imaging parameters and quantitative scores from primary colorectal tumors, we developed a predictive model for the risk of liver metastasis to evaluate the model's predictive value and clinical significance for colorectal cancer liver metastasis. Methods 120 patients with colorectal cancer admitted to Affiliated Hospital of Sichuan Nursing Vocational College (the Thired People's Hospital of Sichuan Province) and the Second Affiliated Hospital of Chengdu Medical College (China National Nuclear Corporation 416 Hospital) between February 2021 and February 2026 were selected. Patients who developed liver metastases were assigned to the metastasis group (n=42), while those without metastases were assigned to the non-metastasis group (n=78). All patients underwent ultrasound quantitative scoring and ultrasound blood flow imaging. The ultrasound blood flow imaging parameters, including end-diastolic velocity (EDV), resistance index (RI), peak systolic velocity (PSV) and ultrasound quantitative score, were analyzed. Spearman's correlation analysis was used to examine the relationship between these parameters and liver metastasis, and independent risk factors were identified by univariate and multivariate logistic regression. The clinical utility of the model was evaluated using Bootstrap validation, receiver operating characteristic (ROC) curves, calibration curves and decision curve analysis. Results The RI in the metastasis group (0.59 ± 0.14) was lower than that in the non-metastasis group (0.94 ± 0.16), while the PSV, EDV and ultrasound quantitative scores in the metastasis group were (23.07 ± 6.32) cm/s, (4.30 ± 0.95) cm/s and (3.83 ± 0.91) points, respectively, higher than those in the non-metastasis group [(19.64 ± 1.19) cm/s, (2.75 ± 0.60) cm/s and (2.24 ± 0.70) points]. These differences were statistically significant (P<0.05). Multivariate logistic regression analysis revealed that RI (OR=3.271), PSV (OR=3.796), EDV (OR=4.179), and ultrasound quantitative score (OR=2.832) were independent factors associated with liver metastasis in colorectal cancer. Spearman's correlation analysis revealed that RI was negatively correlated with liver metastasis (r=-0.418, P<0.05), while PSV, EDV and the ultrasound quantitative score were positively correlated with liver metastasis (r=0.527, 0.347, and 0.409, respectively; all P<0.05). The predictive model was presented as a nomogram, the ROC curve shows that the model's AUC for predicting CRLM was 0.844 (95% CI: 0.834~0.935), with an accuracy of 86.67%, a sensitivity of 83.33%, and a specificity of 88.46%. After 1 000 rounds of internal validation using the bootstrap mothod, the adjusted C-index was 0.844, indicating that the model has good discriminatory power. The Hosmer-Lemeshow test (χ2=2.836, P=0.085) suggested a good fit for the nomogram model. The calibration curve closely approximated the diagonal dashed line (slope = 1) and was near the ideal curve, suggesting good calibration. Decision curve analysis showed that the nomogram provided a high net benefit for predicting the risk of liver metastasis in colorectal cancer. Conclusion The combined use of ultrasound blood flow imaging and ultrasound quantitative scoring for the detection of primary colorectal cancer lesions can improve diagnostic efficacy and has good clinical value for predicting the risk of liver metastasis.
    Impact and clinical significance of blood and urine biomarkers and gut microbiota on hepatocellular carcinoma
    Luo Jihang, Liu Puyu, Luo Yawen
    2026, 31(9):  1325-1330. 
    Asbtract ( 3 )   PDF (5167KB) ( 0 )  
    References | Related Articles | Metrics
    Objective This study aimed to explore the underlying causal associations of blood and urinary biomarkers as well as gut microbiota characteristics with the risk of hepatocellular carcinoma (HCC). Methods Mendelian randomization (MR) was adopted for statistical analysis. A multi-dimensional analytical model was established incorporating inverse-variance-weighted (IVW), MR-Egger regression, weighted-median method, and Bayesian weighted Mendelian randomization (BWMR). Bidirectional and mediation MR analyses were further performed to systematically evaluate the causal effects of multi-source biomarkers and gut microbiota on HCC susceptibility. Results Elevated levels of C-reactive protein (CRP) and gamma-glutamyltransferase (GGT), as well as increased abundances of Firmicutes CAG-345 and Klebsiella, were significantly positively correlated with HCC risk (CRP: OR=1.56,P=0.02; GGT; OR=1.74,P<0.01; Firmicutes CAG-345: OR=1.52,P=0.01; CAG-345 sp000433315: OR=1.49, P=0.01; Klebsiella: OR=2.01, P<0.01). Increased urinary potassium level exerted a significant protective effect against HCC (urinary potassium: OR=0.03, P=0.02). Similarly, the enrichment of Blautia sp000436935, Faecalicatena sp002161355, and Leptospirales also conferred prominent protective effects against HCC (Blautia sp000436935: OR=0.61, P=0.01; Faecalicatena sp002161355: OR=0.21, P<0.01; Leptospirales: OR=0.09, P=0.04). Further mediation analysis revealed that the abundance of the genus Blautia played a mediating role, accounting for 14.08% of the total effect (indirect effect value=-0.51) in the mechanism by which urinary potassium reduced HCC risk. Conclusion This study clarified the causal roles of specific metabolic biomarkers and gut microecology in the pathogenesis of HCC.
    Other Liver Diseases
    Treatment response and bile acid composition characteristics in late-onset intrahepatic cholestasis of pregnancy
    Li Yuexin, Qiu Ju, Zhu Shasha, Qian Jin
    2026, 31(9):  1331-1334. 
    Asbtract ( 3 )   PDF (370KB) ( 0 )  
    References | Related Articles | Metrics
    Objective To investigate the therapeutic response to different treatment regimens in patients with late-onset intrahepatic cholestasis of pregnancy (ICP) and to analyze the relationship between bile acid composition characteristics and treatment response. Methods A total of 94 pregnant women diagnosed with late-onset ICP from Rugao People's Hospital between March 2021 and December 2024 were enrolled. According to treatment regimens, patients were divided into a standard treatment group and a combination therapy group, and therapeutic outcomes were compared between the two groups. According to disease severity, patients were categorized into mild ICP and severe ICP groups, and differences in therapeutic efficacy and bile acid composition were analyzed. Patients were further classified into responders and non-responders based on treatment response, and bile acid profile characteristics were compared between these groups. Outcome measures included serum total bile acids (TBA), liver function parameters, improvement of clinical symptoms, and the proportions of bile acid components. Results After treatment, the TBA level in the combination therapy group was lower than that in the standard treatment group [(10.9±5.3) μmol/L vs. (15.8±6.7) μmol/L, P<0.05], with a greater reduction in TBA [(18.2±4.9) μmol/L vs. (12.6±3.0) μmol/L, P<0.05]. The pruritus relief rate (81.8% vs. 62.0%) and overall treatment response rate (77.3% vs. 54.0%) were both significantly higher (P<0.05). The mild ICP group showed a greater percentage reduction in TBA than the severe ICP group [(58.4±21.3)% vs. (37.4±17.2)%, P<0.05], lower post-treatment TBA levels [(11.6±5.8) μmol/L vs. (23.9±8.4) μmol/L, P<0.05], and a higher response rate (72.1% vs 46.2%, P<0.05). Regarding bile acid composition, the severe ICP group exhibited higher proportions of CA [(31.5±7.2)% vs. (24.1±6.3)%], CDCA [(41.2±8.5)% vs. (33.7±7.8)%], LCA [(6.8±2.7)% vs. (4.3±1.9)%], and proportion of conjugated bile acids [(72.4±11.2)% vs. (58.9±10.6)%], but a lower proportion of DCA [(15.4±4.8)% vs. (21.6±5.9)%] (all P<0.05). The non-responder group had higher baseline TBA levels than the responder group [(35.6±11.4) μmol/L vs. (23.7±8.9) μmol/L, P<0.05], with increased proportions of CA, CDCA, and LCA and a decreased proportion of DCA (all P<0.05). Conclusion Treatment response in patients with late-onset ICP is closely associated with treatment regimen, disease severity, and bile acid composition characteristics. Combination therapy can significantly improve clinical outcomes, while alterations in bile acid profiles may influence therapeutic response. Bile acid composition characteristics may serve as potential indicators for assessing disease status and predicting treatment response in late-onset ICP.
    Analysis of clinical characteristics, biochemical indicators and their relationship with prognosis in neonatal cholestasis
    Cai Yarong, Yang Ning, Ding Ya, Wang Xiao
    2026, 31(9):  1335-1339. 
    Asbtract ( 3 )   PDF (520KB) ( 0 )  
    References | Related Articles | Metrics
    Objective To identify clinical features and biochemical indices related to the prognosis of neonatal cholestasis (NC) and to evaluate their value in clinical management. Methods A total of 142 neonates diagnosed with NC in Northwest Women and Children's Hospital between January 2020 and June 2025 were enrolled and divided into an improvement group (36 cases) and a cure group (106 cases) based on discharge outcomes. Serum levels of alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamyl transferase (γ-GT), total bilirubin (TBil), direct bilirubin (DBil) and alkaline phosphatase were measured by enzymatic and diazonium methods. Binary logistic regression was used to identify factors independently associated with improvement rather than cure at discharge. Receiver operating characteristic (ROC) curves were generated to evaluate the discriminatory value of relevant indicators for cure versus improvement at discharge. Results The improvement group showed a longer disease course (30.9±3.6 vs. 26.2±3.9 days), younger gestational age (29.5±4.0 vs. 31.4±3.7 weeks), lower birth weight (1.2±0.4 vs. 1.5±0.5 kg), longer parenteral nutrition duration (35.2±4.2 vs. 31.3±4.0 days) and longer fasting duration (12.9±2.9 vs. 9.0±2.5 days) compared with the cure group (all P<0.05). The rates of bacterial infection (86.1% vs. 35.9%) and cytomegalovirus (CMV) infection (41.7% vs. 12.3%) were significantly higher in the improvement group (both P<0.05). Levels of ALT (220.3±42.7 vs. 155.8±59.1 U/L), AST (172.4±52.6 vs. 112.5±42.6 U/L), γ-GT (288.9±83.9 vs. 228.9±59.6 U/L), TBil (211.1±75.7 vs. 136.3±48.3 μmol/L) and DBil (149.9±69.8 vs. 104.0±41.1 μmol/L) were also markedly higher in the improvement group (all P<0.05). Multivariate logistic regression analysis showed that fasting duration, AST, TBil and DBil were independently associated with improvement rather than cure at discharge. The AUC values of single indicators were 0.847, 0.812, 0.795 and 0.695 respectively. Combined assessment of the four indicators yielded an AUC of 0.974, with a sensitivity of 94.4% and a specificity of 93.4%. Conclusion Disease course and parenteral nutrition duration are associated with discharge outcomes in neonates with NC. Fasting duration, AST, TBil and DBil are independent factors associated with improvement rather than cure at discharge, and their combination shows good discriminatory performance between the two outcomes.
    Etiological spectrum and clinical characteristics of liver injury caused by non-hepatotropic viral infections in children
    Zhu Xiaoyu, Li Meilin, Wang Yue, Zhao Hemeng, Yao Yuqian
    2026, 31(9):  1340-1343. 
    Asbtract ( 3 )   PDF (401KB) ( 0 )  
    References | Related Articles | Metrics
    Objective To investigate the etiological spectrum of liver injury caused by non-hepatotropic viral infections in children and to compare differences in clinical manifestations, severity of liver dysfunction, and clinical outcomes among different viral infections, in order to provide evidence for clinical diagnosis and management. Methods Clinical data of children with non-hepatotropic viral infections complicated by liver injury, who were hospitalized in Lianyungang First People's Hospital between January 2023 and September 2025, were analyzed. According to etiological test results, patients were divided into the Epstein-Barr virus (EBV) group, cytomegalovirus (CMV) group, influenza virus (FLU) group, and respiratory syncytial virus (RSV) group. Clinical manifestations, liver biochemical parameters, and clinical outcomes were compared among the groups. Results A total of 139 children were enrolled, among whom EBV infection accounted for 63.3% (88/139). The incidence of high fever was highest in the FLU group [85.7% (18/21)], which was significantly higher than that in the CMV group [38.1% (8/21), P<0.05]. The incidences of tonsillar enlargement [88.6% (78/88)] and cervical lymphadenopathy [69.3% (61/88), P<0.05] in the EBV group were significantly higher than those in the other groups. Myalgia was most common in the FLU group [66.7% (14/21)], whereas wheezing was most frequently observed in the RSV group [66.7% (6/9), P<0.05]. Comparison of liver biochemical parameters showed that the EBV group had the highest ALT, AST, and GGT levels, reaching 186 (102, 356) U/L, 172 (96, 318) U/L, and 96 (58, 168) U/L, respectively, all significantly higher than those in the other groups (all P<0.05). The CMV group had relatively higher TBil levels [24.1 (15.6, 41.3) μmol/L, P<0.05]. The EBV group had the longest hospital stay and ALT recovery time, which were 10 (8, 14) days and 24 (18, 35) days, respectively, whereas the FLU group had the shortest hospital stay [7 (5, 9) days] and ALT recovery time [14 (10, 20) days] (all P<0.05). The complete recovery rate of liver function was high in all groups (97.7%~100.0%), and no cases of liver failure or death were observed. Conclusion Non- hepatotropic viral infections in children can lead to varying degrees of liver injury. Differences exist among viruses in terms of clinical manifestations and severity of liver damage. Liver injury caused by EBV infection tends to be more severe and associated with a longer recovery time, whereas liver enzyme elevations related to FLU and RSV infections are generally mild and reversible. The overall prognosis is favorable. Comprehensive evaluation based on etiological findings and clinical characteristics, along with dynamic monitoring, is recommended in clinical practice.
    LCBDE and ERCP for common bile duct stones: a comparative clinical study
    Zhang Jiashen, Zhu Zhencheng, Liu Qiuhua, Zhang Bo, Lu Yuanji
    2026, 31(9):  1344-1347. 
    Asbtract ( 3 )   PDF (416KB) ( 0 )  
    References | Related Articles | Metrics
    Objective To investigate the relative clinical value of laparoscopic common bile duct exploration (LCBDE) and endoscopic retrograde cholangiopancreatography (ERCP) in patients with common bile duct stones by analyzing perioperative outcomes and mid-term follow-up results. Methods According to the different treatment methods, 102 patients with common bile duct stones in Zhangjiagang First People's Hospital from January 2023 to June 2025 were divided into LCBDE group and ERCP group. Parameters related to treatment completeness, complications related to biliary structural and functional integrity, postoperative recovery quality, and outcomes at 6-month follow-up were compared between the two groups. Results The one-stage stone clearance rate was 96.2% (50/52) in the LCBDE group, which was significantly higher than 84.0% (42/50) in the ERCP group (P<0.05). The incidences of residual stones (3.8% vs. 16.0%), repeat intervention (3.8% vs. 18.0%), and treatment failure (0 vs. 8.0%) were all lower in the LCBDE group than in the ERCP group (all P<0.05). Regarding complications related to biliary physiological integrity, the incidence of sphincter of Oddi injury was 22.0% in the ERCP group, significantly higher than 0 in the LCBDE group (P<0.05). The rates of postoperative cholangitis (18.0% vs. 3.8%) and bile reflux gastritis (14.0% vs. 1.9%) were also higher in the ERCP group (all P<0.05). In terms of postoperative recovery, the ERCP group resumed oral intake earlier than the LCBDE group [(24.8±6.7) h vs. (36.5±8.2) h], and had a shorter hospital stay [(6.5±1.1) d vs. (7.1±1.3) d] (both P<0.05). At the 6-month follow-up, the LCBDE group demonstrated significantly lower rates of stone recurrence (1.9% vs. 12.0%), biliary-related readmission (3.8% vs. 16.0%), and repeat biliary intervention rate (1.9% vs. 14.0%) compared with the ERCP group (all P<0.05). Conclusion LCBDE achieves superior one-stage stone clearance, better preserves the physiological structure of the bile duct, and reduces mid-term risks of stone recurrence and re-intervention. ERCP, on the other hand, offers advantages in early postoperative recovery. Both approaches possess specific indications; therefore, treatment selection should be tailored according to individual patient characteristics.
    The expression of 14-3-3θ and TIMP3 in gallbladder cancer tissue and their relationship with clinical pathological features and prognosis of patients
    Li Qiang, Li Ying, Liu Xing, Huang Yanjie, Zhao Chen, Dai Jianguo
    2026, 31(9):  1348-1354. 
    Asbtract ( 3 )   PDF (1773KB) ( 0 )  
    References | Related Articles | Metrics
    Objective To investigate the expression of 14-3-3θ and tissue inhibitor of metalloproteinase (TIMP) 3 in gallbladder cancer tissue and their relationship with clinical pathological features and prognosis of patients. Methods A total of 113 patients with gallbladder cancer admitted to Zhangjiakou First Hospital from March 2020 to June 2021 were regarded as the research subjects. Immunohistochemistry was applied to detect the expression of 14-3-3θ and TIMP3 in gallbladder cancer and its adjacent tissues. Kaplan-Meier curve was applied to analyze the relationship between the expression of 14-3-3θ and TIMP3 in gallbladder cancer tissue and prognosis. Multivariate Cox regression was applied to analyze the factors influencing the prognosis of gallbladder cancer. Results Compared with adjacent tissues (32/113, 28.32%), the positive expression rate of 14-3-3θ (85/113, 75.22%) was higher in gallbladder cancer tissues (χ2=48.779, P<0.05), and the positive expression rate of TIMP3 (31/113, 27.43%) was lower (χ2=59.769, P<0.05). The expression of 14-3-3θ and TIMP3 in gallbladder cancer tissue was related to differentiation degree (χ2=5.509, 6.023) and TNM staging (χ2=8.203, 7.636) (P<0.05). The three-year overall survival rate of 113 patients with gallbladder cancer was 51.33%. Compared with the survival group [19/58, 32.76%; 10/58, 17.24%; (61.62 ± 11.48) U/mL; (80.45 ± 13.16) U/mL], the proportions of low/undifferentiated (35/55, 63.64%) and TNM stage Ⅲ (27/55, 49.09%), as well as the levels of carbohydrate antigen (CA) -125 [(84.51 ± 13.95) U/mL] and CA 19-9 [(106.23 ± 16.37) U/mL] in the death group were significantly higher (P<0.05). Compared with the survival group (38/85, 44.71%), the death group had a higher positive expression rate of 14-3-3θ in gallbladder cancer tissue (47/85, 55.29%) (χ2=6.020, P<0.05), and a lower positive expression rate of TIMP3 (9/31, 29.03%) (χ2=6.596, P<0.05). Multivariate Cox regression analysis showed that The degree of differentiation (HR=1.846), TNM stage (HR=2.059), 14-3-3θ (HR=1.562), TIMP3 (HR=0.913), CA-125 (HR=1.781), and CA19-9 (HR=1.906) were related to the prognosis of gallbladder cancer (P<0.05). Kaplan-Meier analysis showed that the three-year overall survival rate (44.71%) of patients with 14-3-3θ positive expression was lower than that of patients with 14-3-3θ negative expression (71.43%) (Log Rank χ2=5.627, P=0.018). The three-year overall survival rate of TIMP3 positive expression patients (70.97%) was higher than that of TIMP3 negative expression patients (43.90%) (Log Rank χ2=6.130, P=0.013). Conclusion The positive expression rate of 14-3-3θ is higher in gallbladder cancer tissue, while the positive expression rate of TIMP3 is lower. The expression of 14-3-3θ and TIMP3 in gallbladder cancer tissue is closely related to the clinical pathological features and prognosis of patients.